ELUT · Elutia Inc.
$1.00
+0.06 (+6.16%)
At close · Aug 17
Market Cap
$43.40M
Shares
44.29M
Elutia Inc. Earnings Call Transcripts
Every quarterly earnings call for Elutia Inc. (ELUT) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲3.9%
$12.64M
−$9.40M
'22 Q2
22-08-11
▼49.1%
$5.85M
−$9.91M
'22 Q3
22-11-17
▼44.4%
$6.39M
−$7.97M
'23 Q1
23-05-10
▼49.7%
$6.35M
−$10.62M
'23 Q2
23-08-14
▲4.8%
$6.13M
−$9.75M
'23 Q3
23-11-13
·
$5.88M
−$9.31M
'23 Q4
24-03-07
▲4.7%
$6.69M
−$17.99M
'24 Q1
24-05-09
▼0.9%
$6.29M
−$28.18M
'24 Q2
24-08-07
▼40.2%
$3.66M
$1.29M
'24 Q3
24-11-14
▼137.1%
$
−$9.06M
'24 Q4
25-02-03
▼55.9%
$2.95M
−$3.93M
'25 Q1
25-05-08
▼56.3%
$2.75M
−$9.61M
'25 Q2
25-08-14
▼9.3%
$3.32M
−$3.87M
'25 Q3
25-11-06
·
$3.27M
$70.79M
'25 Q4
26-03-11
▲5.5%
$3.11M
−$7.47M
'26 Q1
26-05-14
LATEST
▼11.6%
$2.43M
−$7.65M
'26 Q2
26-08-13
Earnings call
FY26 · Q2
2026-08-13
Elutia Inc. Q2 FY2026 Earnings Call
Revenue
$2.43M
▼ 11.6% YoY Diluted EPS
$-0.17
Gross margin
59.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-14
Elutia Inc. Q1 FY2026 Earnings Call
Confident tone
NXT 41/NXT 41X regulatory progress
Post-operative infection and complications
Automated manufacturing platform
Revenue
$3.11M
▲ 5.5% YoY Diluted EPS
$-0.17
Gross margin
57.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-11
Elutia Inc. Q4 FY2025 Earnings Call
Confident tone
41X Breast Reconstruction Drug-Eluting Platform
Regulatory Pathway (NXT 41 then 41X)
Clinical Efficacy and Data (Plate and Powder)
Revenue
$3.27M*
Gross margin
58.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Elutia Inc. Q3 FY2025 Earnings Call
Confident tone
SimpliDerm commercialization
Breast reconstruction opportunity (NXT-41x)
Boston Scientific sale / transaction validation
Revenue
$3.32M
▼ 9.3% YoY Diluted EPS
$-0.19
Gross margin
55.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Elutia Inc. Q2 FY2025 Earnings Call
Confident tone
EluPro commercial launch and growth
Breast reconstruction pipeline / NXT-41
Business development / strategic transactions
Revenue
$2.75M
▼ 56.3% YoY Diluted EPS
$-0.26
Gross margin
52.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Elutia Inc. Q1 FY2025 Earnings Call
Confident tone
EluPro launch performance
Boston Scientific partnership
Manufacturing capacity
Revenue
$2.95M
▼ 55.9% YoY Diluted EPS
$-0.21
Gross margin
46.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-03
Elutia Inc. Q4 FY2024 Earnings Call
Confident tone
EluPro product launch
Market opportunity vs. Medtronic TYRX
Boston Scientific distribution partnership
Revenue
$*
▼ 137.1% YoY Gross margin
32.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Elutia Inc. Q3 FY2024 Earnings Call
Confident tone
EluPro Product Launch
SimpliDerm Performance
Financial Performance
Revenue
$3.66M
▼ 40.2% YoY Diluted EPS
$-0.33
Gross margin
48.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Elutia Inc. Q2 FY2024 Earnings Call
Revenue
$6.29M
▼ 0.9% YoY Diluted EPS
$-1.13
Gross margin
44.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Elutia Inc. Q1 FY2024 Earnings Call
Confident tone
CanGarooRM FDA clearance and launch readiness
Market opportunity vs. TYRX/Medtronic
SimpliDerm commercial momentum
Revenue
$6.69M
▲ 4.7% YoY Diluted EPS
$-0.75
Gross margin
42.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-07
Elutia Inc. Q4 FY2023 Earnings Call
Confident tone
CanGarooRM FDA clearance and launch
CanGaroo legacy product
SimpliDerm growth
Revenue
$5.88M*
Gross margin
36.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-13
Elutia Inc. Q3 FY2023 Earnings Call
Revenue
$6.13M
▲ 4.8% YoY Diluted EPS
$-0.57
Gross margin
46.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Elutia Inc. Q2 FY2023 Earnings Call
Revenue
$6.35M
▼ 49.7% YoY Diluted EPS
$-0.65
Gross margin
42.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Elutia Inc. Q1 FY2023 Earnings Call
Revenue
$6.39M
▼ 44.4% YoY Diluted EPS
$-0.49
Gross margin
52.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q3
2022-11-17
Elutia Inc. Q3 FY2022 Earnings Call
Revenue
$5.85M
▼ 49.1% YoY Diluted EPS
$-0.73
Gross margin
50.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Elutia Inc. Q2 FY2022 Earnings Call
Revenue
$12.64M
▲ 3.9% YoY Diluted EPS
$-0.69
Gross margin
38.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Elutia Inc. Q1 FY2022 Earnings Call
Revenue
$11.49M
▼ 10.8% YoY Diluted EPS
$-0.60
Gross margin
37.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q3
2021-10-25
Elutia Inc. Q3 FY2021 Earnings Call
Revenue
$11.48M
▼ 2.5% YoY Diluted EPS
$-0.81
Gross margin
32.1%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Elutia Inc. Q2 FY2021 Earnings Call
Revenue
$12.16M
▲ 41.7% YoY Diluted EPS
$-0.23
Gross margin
46.2%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Elutia Inc. Q1 FY2021 Earnings Call
Revenue
$12.88M
▲ 30.6% YoY Diluted EPS
$-0.50
Gross margin
49.1%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-01
Elutia Inc. Q4 FY2020 Earnings Call
Revenue
$12.47M*
Gross margin
48.3%
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-19
Elutia Inc. Q3 FY2020 Earnings Call
Revenue
$11.77M
▲ 5.7% YoY Diluted EPS
$-15.79
Gross margin
47.1%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–22 of 22 earnings calls
Key facts
CIK
1708527
CUSIP
05479K106
13F (30d)
39 filings
38 filers
Visit website
Investor relations